Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

Nasal challenge with allergen leads to maxillary sinus inflammation

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

House dust mite avoidance measures improve peak flow and symptoms in patients with allergy but without asthma: A possible delay in the manifestation of.

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Is 9 more than 2 also in allergic airway inflammation?

Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment Laura Van Gerven, MD, PhD, Yeranddy.

Children with allergic and nonallergic rhinitis have a similar risk of asthma Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

T-cell regulation in chronic paranasal sinus disease

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Self-Medication in Persistent Rhinitis: Overuse of Decongestants in Half of the Patients Els Mehuys, MPharm, PhD, Philippe Gevaert, MD, PhD, Guy Brusselle,

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

René van Gent, MD, Cornelis K. van der Ent, MD, PhD, Maroeska M

The quest for autoreactive antibodies in nasal polyps

TGF-β signaling and collagen deposition in chronic rhinosinusitis

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease Nan Zhang, MD, PhD, Thibaut Van Zele, MD, PhD, Claudina.

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

One step forward, 2 steps back: The enigma of preschool wheeze

Biology of nasal polyposis

Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma Anne E. Dixon, MA, BM BCh,

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps Joke Patou, MD, Philippe Gevaert, MD, PhD, Thibaut.

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

Nasal challenge with allergen leads to maxillary sinus inflammation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Macrolide antibiotics and asthma treatment

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Presentation transcript:

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele, MD, PhD, Katrien Blomme, MSc, Natalie De Ruyck, MSc, Wouter Bauters, MD, PhD, Peter Hellings, MD, PhD, Guy Brusselle, MD, PhD, Dirk De Bacquer, MD, PhD, Paul van Cauwenberge, MD, PhD, Claus Bachert, MD, PhD Journal of Allergy and Clinical Immunology Volume 131, Issue 1, Pages 110-116.e1 (January 2013) DOI: 10.1016/j.jaci.2012.07.047 Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Number of patients who were screened, enrolled, and assigned to a study group and who completed the study. Journal of Allergy and Clinical Immunology 2013 131, 110-116.e1DOI: (10.1016/j.jaci.2012.07.047) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 TPS: change from baseline over weeks based on last-observation-carried-forward imputation in the placebo-treated (solid squares) and omalizumab-treated (open circle) groups. Error bars indicate 95% CIs of the mean based on normal approximation. Journal of Allergy and Clinical Immunology 2013 131, 110-116.e1DOI: (10.1016/j.jaci.2012.07.047) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Change from baseline in nasal congestion (A), anterior rhinorrhea (B), sense of smell (C), wheezing (D), dyspnea (E), and cough (F) in the omalizumab-treated (open circles) and placebo-treated (solid squares) groups. P values represent the change from baseline after 16 weeks of treatment. Error bars indicate 95% CIs of the mean based on normal approximation. Journal of Allergy and Clinical Immunology 2013 131, 110-116.e1DOI: (10.1016/j.jaci.2012.07.047) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Improvement in AQLQ scores after treatment with omalizumab (open columns) or placebo (solid columns). Changes from baseline in the different domains of the AQLQ and the total AQLQ score after 16 weeks of treatment are shown. *Significant improvement for activity limitation (P = .002), symptoms (P = .01), emotional function (P = .02), and total AQLQ (P = .003) scores. Journal of Allergy and Clinical Immunology 2013 131, 110-116.e1DOI: (10.1016/j.jaci.2012.07.047) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions